Investigation Announced on Behalf of ImmunityBio, Inc by Law Offices of Howard G. Smith
July 7, 2023
🌥️Trending News
IMMUNITYBIO ($NASDAQ:IBRX): ImmunityBio, Inc. is a biopharmaceutical company that focuses on the development of innovative immunotherapies for cancer and infectious diseases. These investors are now the subject of an investigation by the Law Offices of Howard G. Smith. The investigation is focused on determining whether ImmunityBio, Inc. and certain of its officers and/or directors have breached their fiduciary duties to the company’s shareholders.
Share Price
This is the latest development for the biotechnology company, as their stock has been unstable in recent months. Further details regarding the investigation have yet to be released. ImmunityBio_Inc_by_Law_Offices_of_Howard_G._Smith”>Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Immunitybio. ImmunityBio_Inc_by_Law_Offices_of_Howard_G._Smith”>More…
| Total Revenues | Net Income | Net Margin |
| 0.59 | -430.08 | -76949.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Immunitybio. ImmunityBio_Inc_by_Law_Offices_of_Howard_G._Smith”>More…
| Operations | Investing | Financing |
| -346.89 | 88.13 | 310.8 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Immunitybio. ImmunityBio_Inc_by_Law_Offices_of_Howard_G._Smith”>More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 343.4 | 875.12 | -1.21 |
Key Ratios Snapshot
Some of the financial key ratios for Immunitybio are shown below. ImmunityBio_Inc_by_Law_Offices_of_Howard_G._Smith”>More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -52.2% | – | -59049.7% |
| FCF Margin | ROE | ROA |
| -69305.8% | 44.3% | -63.0% |
Analysis
GoodWhale recently analyzed IMMUNITYBIO’s financials using our proprietary Star Chart. It appears that IMMUNITYBIO is strong in asset and dividend, but weak in growth and profitability. After analyzing IMMUNITYBIO’s financials, we concluded that the company is classified as an ‘elephant’ which is a type of company that has relatively high assets after deducting off liabilities. Given its financials, investors who are interested in a company with strong assets and dividends may be interested in investing in IMMUNITYBIO. However, we do caution investors that IMMUNITYBIO has a very low health score of 2/10 with regard to its cashflows and debt, which means it is less likely to safely ride out any crisis without the risk of bankruptcy. More…
Peers
The biotech industry is fiercely competitive, and ImmunityBio Inc is up against some stiff competition. Its main competitors are Sensei Biotherapeutics Inc, Caribou Biosciences Inc, and Bolt Biotherapeutics Inc. All of these companies are vying for a piece of the pie in the immunotherapy market, and each has its own unique approach to treatment. ImmunityBio Inc has a strong track record and is well-positioned to continue its success in the face of stiff competition.
– Sensei Biotherapeutics Inc ($NASDAQ:SNSE)
In 2022, Sensei Biotherapeutics Inc had a market cap of 44.85M and a Return on Equity of -31.43%. The company is engaged in the research, development and commercialization of cancer immunotherapy products. Its products are designed to harness the power of the immune system to kill cancer cells.
– Caribou Biosciences Inc ($NASDAQ:CRBU)
Caribou Biosciences Inc is a leading edge biotechnology company that is focused on developing innovative CRISPR-based gene editing tools and therapeutics. The company has a market cap of 571.3M as of 2022 and a return on equity of -24.1%. Caribou’s mission is to empower the scientific community to cure disease and improve our quality of life. The company’s products are based on its proprietary CRISPR-Cas9 technology, which is a powerful tool for genome editing. Caribou’s products are used by scientists around the world to study a wide range of diseases and to develop new therapeutics. Caribou is headquartered in Berkeley, California.
– Bolt Biotherapeutics Inc ($NASDAQ:BOLT)
Bolt Biotherapeutics Inc is a clinical stage immuno-oncology company. The company is engaged in developing immunotherapies based on its Antibody-Oligonucleotide Conjugates (AOCs) platform. The company’s lead product candidate is BTA-A1, an AOC targeting antigens expressed in a variety of solid tumors. The company is also developing other product candidates, including BT-A02, BT-A03 and BT-A04, which are in preclinical development.
As of 2022, Bolt Biotherapeutics Inc has a market cap of 54.58M and a Return on Equity of -44.7%. The company’s lead product candidate, BTA-A1, is currently in clinical development. The company is also developing other product candidates which are in preclinical development.
Summary
Investors should keep an eye out for ImmunityBio, Inc. after the Law Offices of Howard G. Smith announced an investigation into the company. The investigation has caused ImmunityBio’s stock price to drop on the same day that it was announced. While the reasons behind the investigation remain undisclosed, investors should monitor the situation carefully as this could have an impact on the company’s performance in the future. Those considering investing in ImmunityBio should do their due diligence and research any potential risks before making any decisions.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
